ImmuneOncia Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in South Korea (KR), is at the forefront of developing innovative immunotherapies for cancer treatment. Founded in 2015, the company has rapidly established itself within the biotechnology industry, focusing on the discovery and development of novel therapeutic agents that harness the body's immune system to combat malignancies. ImmuneOncia's core offerings include cutting-edge monoclonal antibodies and immune-modulating therapies, distinguished by their unique mechanisms of action and potential to improve patient outcomes. With a strong emphasis on research and development, the company has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing cancer care. As a leader in the immuno-oncology sector, ImmuneOncia Therapeutics continues to make strides in transforming the landscape of cancer treatment.
We don't have data for ImmuneOncia Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company